Markus Kirolos Youssef (Markus K Youssef)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Transforming Growth Factor

Metastatic Colorectal Cancer

Immune Response

Top Venues

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Luigi Mazzeo, Soumitra Ghosh, Emery Di Cicco, Jovan Isma, Daniele Tavernari, Anastasia Samarkina, Paola Ostano, Markus Kirolos Youssef, Christian Simon, Gian Paolo Dotto
ANKRD1 is a mesenchymal-specific driver of cancer-associated fibroblast activation bridging androgen receptor loss to AP-1 activation. Nature communications 15 (1) (2024)
Luigi Mazzeo, Soumitra Ghosh, Emery Di Cicco, Jovan Isma, Daniele Tavernari, Anastasia Samarkina, Paola Ostano, Markus Kirolos Youssef, Christian Simon, Gian Paolo Dotto
ANKRD1 is a mesenchymal-specific driver of cancer-associated fibroblast activation bridging androgen receptor loss to AP-1 activation. Nature communications 15 (1) (2024)
Luigi Mazzeo, Soumitra Ghosh, Emery Di Cicco, Jovan Isma, Daniele Tavernari, Anastasia Samarkina, Paola Ostano, Markus Kirolos Youssef, Christian Simon, Gian Paolo Dotto
ANKRD1 is a mesenchymal-specific driver of cancer-associated fibroblast activation bridging androgen receptor loss to AP-1 activation. Nature communications 15 (1) (2024)
Luigi Mazzeo, Soumitra Ghosh, Emery Di Cicco, Jovan Isma, Daniele Tavernari, Anastasia Samarkina, Paola Ostano, Markus Kirolos Youssef, Christian Simon, Gian Paolo Dotto
ANKRD1 is a mesenchymal-specific driver of cancer-associated fibroblast activation bridging androgen receptor loss to AP-1 activation. Nature communications 15 (1) (2024)
Anastasia Samarkina, Markus Kirolos Youssef, Paola Ostano, Soumitra Ghosh, Min Ma, Beatrice Tassone, Tatiana Proust, Giovanna Chiorino, Mitchell P Levesque, Sandro Goruppi, Gian Paolo Dotto
Androgen receptor is a determinant of melanoma targeted drug resistance. Nature communications 14 (1) (2023)